8.43
-0.24%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CSPC Pharmaceutical Group
Its shares trade on HKEX under the ticker 1093.HK. It has been listed since 21 June 1994. In the fiscal year to 31 December 2025, it reported revenue of CN¥29.49bn and net income of CN¥4.40bn. At that date it held total assets of CN¥54.38bn and shareholders' equity of CN¥38.63bn.
CSPC Pharmaceutical Group Ltd. is an investment holding company, which is engaged in the manufacturing and selling of pharmaceutical products. The company is headquartered in Shijiazhuang, Hebei. The firm sells its products under the brand of CSPS. The firm has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The firm is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 21 Jun 1994
- Employees
- 17,292
- Website
- cspc.com.hk ↗
Leadership
Pay as last reported
- Mr. Dongchen CaiExecutive Chairman of the Board, since 1998CN¥26.7m
- Mr. Cuilong ZhangExecutive Vice Chairman of the Board, Chief Executive Officer, since 2018CN¥13.5m
- Mr. Xin CaiExecutive Director, since 2024
- Mr. Weiping ChenExecutive Director, since 2024
- Mr. Chunlei LiExecutive Director, since 2017CN¥9.4m
- Mr. Weidong PanExecutive Director, since 2006CN¥4.9m
- Mr. Huaiyu WangExecutive Director, since 2010CN¥5.7m
- Mr. Zhenguo WangExecutive Director, since 2012CN¥4.9m
- Dr. Bing YaoExecutive Director, since 2024
- Mr. Tain On LoCompany Secretary
- Mr. Chun Kwok AuIndependent Non-Executive DirectorCN¥340,000
- Mr. Chuan ChenIndependent Non-Executive DirectorCN¥142,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 76
- Environment
- 74
- Social
- 88
- Governance
- 67
- Direct emissions (scope 1)
- 663,224 t
- Energy emissions (scope 2)
- 418,037 t
- Women in the workforce
- 48.16014%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CSPC Pharmaceutical Group Ltd has several key strengths that contribute to its success in the pharmaceutical industry. Firstly, the company has a strong portfolio of high-quality and innovative products, which have gained significant market share both domestically and internationally.
- Additionally, CSPC Pharmaceutical Group Ltd has established strong relationships with healthcare providers, distributors, and key stakeholders in the industry. This allows the company to efficiently market and distribute its products and expand its customer base.
Weaknesses
- Despite its successes, CSPC Pharmaceutical Group Ltd faces a few weaknesses that it should address in order to maintain its competitive edge. One weakness is its heavy reliance on a limited number of blockbuster drugs for a significant portion of its revenue. This exposes the company to potential risks if these drugs face regulatory issues or competition from generic alternatives.
- Additionally, CSPC Pharmaceutical Group Ltd operates mainly in the Chinese market, which makes it vulnerable to regulatory changes and economic fluctuations specific to that region. Expanding its presence in other international markets could help mitigate this weakness.
Opportunities
- There are several opportunities that CSPC Pharmaceutical Group Ltd can leverage to drive growth and further strengthen its position in the industry. One opportunity is the increasing demand for healthcare products and services in emerging markets, such as China and other Asian countries. By capitalizing on this trend, the company can expand its customer base and increase its market share.
- Additionally, advancements in technology and research present opportunities for CSPC Pharmaceutical Group Ltd to develop innovative therapies and drug delivery systems. Investing in research and development can help the company stay ahead of competitors and offer cutting-edge products to meet evolving customer needs.
Threats
- CSPC Pharmaceutical Group Ltd faces certain threats that could impact its business operations and growth prospects. One significant threat is increasing competition from both domestic and international pharmaceutical companies. This can result in price pressures, loss of market share, and decreased profitability.
- Moreover, regulatory changes and stringent approval processes for new drugs pose a threat to CSPC Pharmaceutical Group Ltd. Delays in obtaining necessary approvals can impact product launches and revenue generation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.